Metabolic Profile in Patients with Benign Prostate Hyperplasia or Prostate Cancer and Normal Glucose Tolerance

Familial predisposition together with several environmental factors may be involved in the pathogenesis of common prostate disease such as benign hypertrophy or prostate neoplasm. A higher incidence of both these conditions has been described in some insulin-resistant states such as obesity, but not much information is available on the effect of metabolic profile on gland morphology. The aim of this study was to evaluate the relation between glucose and lipid pattern and prostate diameters in two groups of non-diabetic individuals with benign prostate hypertrophy or cancer. 109 patients were recruited; plasma glucose, lipids and hormonal profile as well as an ultrasonographic evaluation of the gland volume and diameters were determined. Patients with prostate cancer had significantly higher levels of insulin and were more insulin resistant; in contrast, in subjects with prostate hypertrophy, fasting plasma glucose and--to a lesser extent--serum triglycerides emerged as the main determinants of gland volume. These observations may indicate that an improvement of insulin sensitivity and strategies to maintain a strict glucose and lipid control even in non-diabetic subjects are useful objectives in the prevention of prostate diseases.

[1]  Steven Shea,et al.  Diabetes Mellitus and the Risk of Prostate Cancer , 2002, Cancer investigation.

[2]  T. Noakes,et al.  Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. , 2001, Atherosclerosis.

[3]  R. Casaburi,et al.  Testosterone dose-response relationships in healthy young men. , 2001, American journal of physiology. Endocrinology and metabolism.

[4]  A. Dyer,et al.  Postload plasma glucose concentration and 27-year prostate cancer mortality (United States) , 2001, Cancer Causes and Control.

[5]  W. Aronson,et al.  Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. , 2001, The Journal of urology.

[6]  M. Barry,et al.  Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. , 2001, Journal of clinical epidemiology.

[7]  J. Isaacs,et al.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. , 2001, Cancer research.

[8]  K. Imaida,et al.  Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. , 2001, Cancer research.

[9]  N. Hotta,et al.  Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity , 2001, Diabetologia.

[10]  J. Benichou,et al.  Body size and prostate cancer: a population-based case-control study in China. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  E. Barrett-Connor,et al.  Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. , 2000, Diabetes care.

[12]  V. Toscano,et al.  ROLE OF ESTROGENS IN HUMAN BENIGN PROSTATIC HYPERPLASIA , 2000, Archives of andrology.

[13]  Gopal Singh,et al.  Regulation of prostate cancer cell division by glucose , 1999, Journal of cellular physiology.

[14]  P. Ekman Genetic and Environmental Factors in Prostate Cancer Genesis:Identifying High-Risk Cohorts , 1999, European Urology.

[15]  W. Satariano,et al.  Cause of death in men diagnosed with prostate carcinoma , 1998, Cancer.

[16]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[17]  P. Cohen,et al.  Serum insulin-like growth factor-I levels and prostate cancer risk--interpreting the evidence. , 1998, Journal of the National Cancer Institute.

[18]  H. Tsuda,et al.  Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. , 1998, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[19]  W. Mcconathy,et al.  Testosterone, Sex Hormone-Binding Globulin, Lipoproteins, and Vascular Disease Risk , 1997, Journal of cardiovascular risk.

[20]  J. Overgaard,et al.  The natural history of prostate carcinoma based on a Danish population treated with no intent to cure , 1997, Cancer.

[21]  Young Soo Kim,et al.  A high-risk group for prostatism: a population-based epidemiological study in Korea. , 1997, British journal of urology.

[22]  P. Moulin,et al.  Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  R. Pasquali,et al.  Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. , 1995, The Journal of clinical endocrinology and metabolism.

[24]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[25]  R. Stock,et al.  Increased serum insulin associated with increased risk of prostate cancer recurrence , 2002, The Prostate.

[26]  E. Barrett-Connor,et al.  Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. , 2002, Diabetes care.

[27]  M. Pollak,et al.  Insulin-like growth factors and prostate cancer. , 2001, Epidemiologic reviews.

[28]  E. Calle,et al.  Is diabetes mellitus associated with prostate cancer incidence and survival? , 1999, Epidemiology.

[29]  R. Kirby Clinical pharmacology of alpha1-adrenoceptor antagonists. , 1999, European urology.

[30]  B. Högstedt,et al.  Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. , 1999, Blood pressure.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[32]  W. Garraway,et al.  Reproducibility and observer variability of transrectal ultrasound measurements of prostatic volume. , 1995, Ultrasound in medicine & biology.

[33]  H. Adlercreutz,et al.  Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors. , 1995, The Journal of clinical endocrinology and metabolism.

[34]  P. Sluss,et al.  Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines , 1993, The Prostate.

[35]  L. Kolonel,et al.  Prostate cancer: a current perspective. , 1991, Epidemiologic reviews.

[36]  C. Muir,et al.  The epidemiology of prostatic cancer. Geographical distribution and time-trends. , 1991, Acta oncologica.